Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
4.530 USD | +4.14% | -2.79% | -60.40% |
Voraussichtliche Gewinn- und Verlustrechnung: Ironwood Pharmaceuticals, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Umsatz 1 | 428.4 | 389.5 | 413.8 | 410.6 | 442.7 | 356.1 | 362.7 | 380.1 |
Veränderung | - | -9.08% | 6.22% | -0.76% | 7.83% | -19.56% | 1.84% | 4.81% |
EBITDA 1 | 147.8 | 160.7 | 233.7 | 251.8 | -884.8 | 80.9 | 91.9 | 183.8 |
Veränderung | - | 8.72% | 45.47% | 7.71% | - | - | 13.6% | 100% |
Betriebsergebnis (EBIT) 1 | 120.1 | 142.9 | 232.2 | 250.3 | -945.4 | 83.52 | 83 | 152.7 |
Veränderung | - | 18.99% | 62.46% | 7.8% | - | - | -0.62% | 83.95% |
Gezahlte Zinsen 1 | -33.74 | -27.97 | -31.15 | -7.598 | -21.63 | -27.8 | -25.87 | -21.5 |
Gewinn vor Steuern (EBT) 1 | 21.5 | 108.9 | 200.7 | 252.4 | -948.1 | 67.02 | 58.52 | 102.7 |
Veränderung | - | 406.21% | 84.32% | 25.8% | - | - | -12.68% | 75.48% |
Nettoergebnis 1 | 21.5 | 106.2 | 528.4 | 175.1 | -1’002 | 16.48 | 34.22 | 56.33 |
Veränderung | - | 393.73% | 397.71% | -66.87% | - | - | 107.74% | 64.6% |
Datum der Veröffentlichung | 13.02.20 | 17.02.21 | 17.02.22 | 16.02.23 | 15.02.24 | - | - | - |
Vorläufige Bilanz: Ironwood Pharmaceuticals, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Nettoverschuldung | 231 | 70.8 | -166 | -260 | - | - | - | - |
Veränderung | - | -69.35% | -334.46% | -256.63% | - | - | - | - |
Datum der Veröffentlichung | 13.02.20 | 17.02.21 | 17.02.22 | 16.02.23 | 15.02.24 | - | - | - |
Prognostizierter Cashflow: Ironwood Pharmaceuticals, Inc.
Steuerjahr: Dezember | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX Investitionsaufwand 1 | 11.41 | 1.842 | 0.265 | 0.136 | 0.273 | 0.35 | 0.35 | 0.5 |
Veränderung | - | -83.86% | -85.61% | -48.68% | 100.74% | 28.21% | 0% | 42.86% |
Free Cashflow (FCF) 1 | -0.687 | 167 | 261.6 | 273.6 | 183.2 | 133.6 | 115.5 | - |
Veränderung | - | -24’407.71% | 56.67% | 4.59% | -33.06% | -27.06% | -13.55% | -100% |
Datum der Veröffentlichung | 13.02.20 | 17.02.21 | 17.02.22 | 16.02.23 | 15.02.24 | - | - | - |
Voraussichtliche Finanzkennzahlen: Ironwood Pharmaceuticals, Inc.
Steuerjahr: Dezember | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|---|
Rentabilität | |||||||||
EBITDA-Marge (%) | - | 34.5% | 41.25% | 56.49% | 61.31% | -199.85% | 22.72% | 25.34% | 48.35% |
EBIT-Marge (%) | - | 28.04% | 36.7% | 56.12% | 60.97% | -213.54% | 23.45% | 22.89% | 40.16% |
EBT-Marge (%) | - | 5.02% | 27.95% | 48.5% | 61.48% | -214.14% | 18.82% | 16.14% | 27.02% |
Nettogewinn (%) | - | 5.02% | 27.26% | 127.72% | 42.64% | -226.37% | 4.63% | 9.44% | 14.82% |
FCF-Marge N (%) | - | -0.16% | 42.87% | 63.23% | 66.64% | 41.37% | 37.51% | 31.85% | - |
FCF / Nettogewinn (%) | - | -3.19% | 157.28% | 49.51% | 156.3% | -18.27% | 810.93% | 337.47% | - |
Rentabilität | |||||||||
ROA | -13.63% | 21% | 20.65% | 17.24% | 14.05% | 15.58% | - | - | - |
ROE | 302.77% | -40.7% | -693.71% | 158.09% | 27.83% | -674.04% | - | - | - |
Finanzielle Gesundheit | |||||||||
Verschuldungsgrad (Verbindlichkeiten/EBITDA) | - | 1.56x | 0.44x | - | - | - | - | - | - |
Verschuldung / Free Cashflow | - | -336.2x | 0.42x | - | - | - | - | - | - |
Kapitalintensität | |||||||||
CAPEX / Umsatz (%) | - | 2.66% | 0.47% | 0.06% | 0.03% | 0.06% | 0.1% | 0.1% | 0.13% |
CAPEX / EBITDA (%) | - | 7.72% | 1.15% | 0.11% | 0.05% | -0.03% | 0.43% | 0.38% | 0.27% |
CAPEX / FCF (%) | - | -1’661.14% | 1.1% | 0.1% | 0.05% | 0.15% | 0.26% | 0.3% | - |
Elemente pro Aktie | |||||||||
Cashflow pro Aktie 1 | - | 0.0687 | 1.051 | - | - | - | - | - | - |
Veränderung | - | - | 1’429.72% | - | - | - | - | - | - |
Dividende pro Aktie 1 | - | - | - | - | - | - | - | - | - |
Veränderung | - | - | - | - | - | - | - | - | - |
Buchwert je Aktie 1 | - | -0.59 | 0.39 | 3.739 | 3.502 | - | - | - | - |
Veränderung | - | - | -166.1% | 858.79% | -6.36% | - | - | - | - |
Gewinn pro Aktie 1 | - | 0.14 | 0.66 | 3.21 | 0.96 | -6.45 | 0.13 | 0.395 | 0.375 |
Veränderung | - | - | 371.43% | 386.36% | -70.09% | -771.88% | -102.02% | 203.85% | -5.06% |
Anz. der Aktien (in Tausend) | - | 156’818 | 160’097 | 163’650 | 153’395 | 156’129 | 159’739 | 159’739 | 159’739 |
Datum der Veröffentlichung | - | 13.02.20 | 17.02.21 | 17.02.22 | 16.02.23 | 15.02.24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
KGV | 34.8x | 11.5x |
KBV | - | - |
EV / Sales | 2.03x | 2x |
Rendite | - | - |
Gewinn pro Aktie & Dividende
Historische Entwicklung KGV
- Börse
- Aktien
- A0X789 Aktie
- Finanzen Ironwood Pharmaceuticals, Inc.
MarketScreener is also available in this country: United States.
Switch edition